ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, the BCR-ABL chimeric oncoprotein which functions as a constitutively active tyrosine kinase is also necessary for disease maintenance; thus, CML provides an ideal model for testing the effects of “targeted therapies”.